2Xideas AG Buys 40,465 Shares of Edwards Lifesciences Co. (NYSE:EW)

2Xideas AG increased its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 25.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 196,508 shares of the medical research company’s stock after acquiring an additional 40,465 shares during the quarter. Edwards Lifesciences makes up about 2.3% of 2Xideas AG’s portfolio, making the stock its 10th largest position. 2Xideas AG’s holdings in Edwards Lifesciences were worth $18,778,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Martin Capital Advisors LLP grew its position in Edwards Lifesciences by 0.5% in the 4th quarter. Martin Capital Advisors LLP now owns 25,490 shares of the medical research company’s stock valued at $1,944,000 after purchasing an additional 128 shares during the period. Chapin Davis Inc. grew its holdings in shares of Edwards Lifesciences by 1.7% during the first quarter. Chapin Davis Inc. now owns 8,548 shares of the medical research company’s stock valued at $817,000 after buying an additional 140 shares during the last quarter. Johnson Financial Group Inc. increased its position in shares of Edwards Lifesciences by 23.0% during the fourth quarter. Johnson Financial Group Inc. now owns 771 shares of the medical research company’s stock worth $59,000 after acquiring an additional 144 shares in the last quarter. Valley National Advisers Inc. raised its holdings in shares of Edwards Lifesciences by 6.0% in the 1st quarter. Valley National Advisers Inc. now owns 2,677 shares of the medical research company’s stock worth $255,000 after acquiring an additional 152 shares during the last quarter. Finally, Choreo LLC lifted its position in Edwards Lifesciences by 4.1% in the 1st quarter. Choreo LLC now owns 3,840 shares of the medical research company’s stock valued at $367,000 after acquiring an additional 153 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $93.29, for a total value of $466,450.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at approximately $4,378,659.44. The sale was disclosed in a filing with the SEC, which is available through this link. In related news, Director Michael A. Mussallem sold 29,350 shares of the stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $84.77, for a total value of $2,487,999.50. Following the completion of the transaction, the director now directly owns 4,486 shares of the company’s stock, valued at $380,278.22. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total value of $466,450.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at $4,378,659.44. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 73,849 shares of company stock worth $6,381,503. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Down 0.2 %

Shares of EW traded down $0.10 during mid-day trading on Tuesday, reaching $63.64. The company’s stock had a trading volume of 9,057,778 shares, compared to its average volume of 3,850,313. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The stock has a market cap of $38.35 billion, a PE ratio of 27.43, a P/E/G ratio of 2.33 and a beta of 1.11. The company’s fifty day moving average price is $86.92 and its two-hundred day moving average price is $86.84. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The company had revenue of $1.63 billion during the quarter, compared to analyst estimates of $1.65 billion. During the same quarter in the previous year, the company posted $0.66 EPS. Edwards Lifesciences’s revenue for the quarter was up 6.7% on a year-over-year basis. On average, analysts predict that Edwards Lifesciences Co. will post 2.71 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

EW has been the subject of a number of analyst reports. Oppenheimer lowered their price target on Edwards Lifesciences from $100.00 to $90.00 and set an “outperform” rating for the company in a research report on Thursday, July 25th. Bank of America lowered shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating and dropped their price target for the company from $105.00 to $75.00 in a research report on Thursday, July 25th. StockNews.com downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Thursday, July 25th. TD Cowen cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their target price for the stock from $100.00 to $70.00 in a research report on Thursday, July 25th. Finally, Baird R W lowered Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 25th. Fourteen equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $82.10.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.